Erkan Alpaslan

Erkan Alpaslan

Auto-generated profile, based on publicly available information

Erkan Alpaslan

Department of Cardiology Izmir Demokrasi University Goztepe Izmir Turkey

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2023 in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
Verified
Journal Article
Closed access
EAErkan Alpaslan
Erkan Alpaslan
STSedat Taş
Sedat Taş
ÜTÜmmü Taş
Ümmü Taş
EOEbru Ozpelit
Ebru Ozpelit
Amaç: Çalışmamızın amacı Vazovagal senkoplu hastalarda hemodinamik mekanizmayı etkileyebilecek kardiyovasküler otonomik modülasyonlardan biri olan arteriyel sertlik parametrelerini değerlendirmek. Gereç ve yöntemler: Çalışmamız retrospektif bir çalışmadır. Ocak 2012-Ocak 2016 tarihleri arasında kardiyoloji polikliniğine başvuran en az iki senkop atağı olan ve eğik masa testi pozitif olan 42 hastanın eğik masa testi sonuçlarını ve arteriyel sertlik parametrelerini topladık. Kontrol grubu olarak da yaş ve cinsiyete göre eşleştirilmiş 41 kişi aldık. Hastalardan damar özelliklerini etkileyebilecek durumları olan, ritim bozukluğu ve psikiyatrik bozukluğu olan hastaları çalışma dışı bıraktık. Hastaların arteriyel sertlik ölçümleri, tilt testi sonuçları, tıbbi öyküleri, sosyodemografik ve klinik bilgileri ile ilgili veriler tıbbi kayıtlarından elde edildi. Arteriyel sertliğinin belirteçleri olarak augmentasyon indeksi, merkezi nabız basıncı ve karotid ila radyal nabız dalga hızı dahil olmak üzere merkezi aort basıncı parametreleri elde edildi. Ardından 2 grup arasında değişkenler karşılaştırıldı. Bulgular: Periferik sistolik (125 ± 16,6 ve 121,1 ± 14,9, p: 0,31) ve diyastolik kan basınçları (79,6 ± 8,9 ve 77,7 ± 9,7, p: 0,38) VVS ve kontrol grupları arasında benzerdi. Merkezi sistolik kan basınçları ve merkezi güçlendirme basınçları da gruplar arasında anlamlı farklılık göstermedi. Vazovagal senkoplu hastalarda nabız dalga hızı sağlıklı kontrollere göre anlamlı derecede düşüktü (5.4 (1.4) and 5.9 (1.8), p= 0.04). Aort augmentasyon indeksi gruplar arasında istatistiksel olarak farklı olmasa da hasta grubunda daha yüksek bulduk. Sonuç: Çalışmamızda VVS grubunda nabız dalga yayılımı sağlıklı gruba göre daha düşük bulundu. Bu sonuçlar VVS hastalarında patofizyolojinin anlaşılmasına katkıda bulunabilir. Vazovagal senkoplu hastalarda nabız dalga hızının önemini anlamak için daha ileri çalışmalara ihtiyaç vardır.


31 August 2023 in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
Verified
Journal Article
Open access
PDF file
EAErkan Alpaslan
Erkan Alpaslan
ÜTÜmmü Taş
Ümmü Taş
STSedat Taş
Sedat Taş
EOEbru Ozpelit
Ebru Ozpelit
Aim: The pathophysiology of vasovagal syncope (VVS) is not completely understood. Some echocardiographic parameters have been defined to contribute to its pathophysiology. However. whether right atrial (RA) and right ventricular (RV) functions have any impact on development of VVS is not well known. In this study we aimed to evaluate the baseline echocardiographic parameters in patients with VVS with special focus on right ventricle and atrium functions. Material and methods: We evaluated the medical records of 42 patients with VVS and 41 age and sex matched healthy subjects. Patients with at least two syncopal attack and positive head-up-tilt test were enrolled in the study. All medical records of echocardiography and head-up-tilt test were obtained. Results: Among left ventricular function parameters, there were no significant difference between the groups. Right ventricle myocardial performance index (p= 0.003) and maximal pulmoner systolic flow velocity (PVmax) (p=0.03) were significantly differ between the groups. RAA was significantly larger (p=0.04) and the ratio of tricuspid filling velocities (E/A), (p=0.01) was significantly lower in VVS group. Conclusions: The findings of the present study indicate a subtle right atrial diastolic dysfunction in patients with VVS. Decreased right atrial contribution to RV filling may cause a lower RV stroke volüme which explains the lower PVmax values in our VVS group. All together, those findings may serve for a tendency to low output states and hypotension as in VVS.

2 October 2025 in Pakistan Heart Journal
Verified
Journal Article
Open access
PDF file
STSedat Taş
Sedat Taş
EAErkan Alpaslan
Erkan Alpaslan
ÜTÜmmü Taş
Ümmü Taş
ABAdnan Bi̇lge
Adnan Bi̇lge
Objectives: Scuba diving places the body under unique environmental stresses, including increased ambient pressure, which can influence cardiovascular function. Understanding echocardiographic parameters in professional scuba divers is essential to assess potential cardiac adaptations and long-term health risks associated with chronic exposure to diving. This study evaluates echocardiographic changes in professional divers compared to non-divers. Methodology: A cross-sectional study was conducted involving 20 professional scuba divers and 22 age-matched non-diver controls. Participants underwent detailed echocardiographic assessments, including measurements of left and right ventricular dimensions, left ventricular mass index (LVMI), and maximum pulmonary velocity (PVmax). Results: Professional divers demonstrated significant echocardiographic differences compared to non-divers. LVMI was significantly higher in divers (84.8 ± 13.8 g/m² vs. 76.2 ± 10.6 g/m², p = 0.03), as was PVmax (1.05 ± 0.13 m/s vs. 0.97 ± 0.1 m/s, p = 0.025). Additionally, divers exhibited increased right ventricular dimensions and a greater prevalence of tricuspid regurgitation. However, left and right ventricular ejection fractions did not differ significantly between the two groups. Conclusion: Professional scuba divers exhibit distinct echocardiographic adaptations, particularly in the right ventricle and pulmonary circulation, likely resulting from chronic exposure to hyperbaric stress and pressure fluctuations. While these adaptations may be physiological, their potential long-term cardiovascular implications warrant further investigation. Future research should focus on longitudinal studies to evaluate the progression of these changes and their clinical significance.


5 January 2026 in Pakistan Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
ODOMER OZKAN DUMAN
OMER OZKAN DUMAN
EAErkan Alpaslan
Erkan Alpaslan
Objective: To compare the changes in levels of inflammation markers in the patient with non-valvular atrial fibrillation (NVAF) who were on Warfarin and then switched to Apixaban. Methodology: The files of 149 consecutive patients, who had NVAF, who were previously using Warfarin, but for various reasons switched to Apixaban were screened retrospectively. Forty-one patients were excluded from the study. Last coagulation parameters were used for analysis. The evaluation of hemogram parameters in patients undergoing treatment with Warfarin, subsequently transitioning to Apixaban, revealed significant insights into various hematological indices. Notably, the Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, the Systemic Immune-Inflammation Index, Systemic Inflammation Response Index (SIRI), the aggregate index of systemic inflammation and Monocyte/Lymphocyte Ratio were meticulously assessed and compared between the groups. Results: The study involved 108 individuals with NVAF. The average lymphocyte level of the patients on Apixaban therapy was statistically significantly higher than on Warfarin therapy (p<0.001). Also, The Neutrophils (p<0.001), Monocytes (p=0.008), and Platelets (p<0.001) were significantly lower in patients treated with Apixaban compared to those on Warfarin. When the systemic inflammation indices of the patients were compared, the averages of the patients’ NLR, PLR, MLR, SII, SIRI, and AISI indices were statistically and significantly lower than time on Warfarin therapy. Conclusion: Current study results suggested that Apixaban has more effective anti-inflammatory potential compared to Warfarin. The study implicates new perspectives on the anti-inflammatory effects of oral anticoagulants used in the treatment of NVAF.